17:07 uur 29-09-2017

Pharnext presenteert op vierde International Neurotech Investing and Partnering Conference

PARIJS–(BUSINESS WIRE)–

Pharnext SA (Paris:ALPHA) (FR00111911287 – ALPHA), een biofarmaceutisch bedrijf met een vernieuwende benadering van geneesmiddelen door reeds bekende medicijnen te combineren en te herpositioneren, heeft vandaag bekendgemaakt dat de directie van het bedrijf een overzicht van de bedrijfszaken presenteert op de vierde International Neurotech Investing and Partnering Conference.

De presentatie heeft plaats op:

  • Datum: woensdag 4 oktober 2017
  • Tijd: 16.00 uur (CEST)
  • Locatie: Wyss Center in Genève, Zwitserland

Pharnext to Present at 4th International Neurotech Investing and Partnering Conference

PARIS–(BUSINESS WIRE)– Regulatory News:

Pharnext SA (FR00111911287 – ALPHA) (Paris:ALPHA), a biopharmaceutical company pioneering a new approach to the development of innovative drugs based on the combination and repositioning of known drugs, today announced that company management will present a corporate overview at the 4th International Neurotech Investing and Partnering Conference.

The presentation will take place as follows:

  • Date: Wednesday, October 4th, 2017
  • Time: 4:00pm CEST
  • Venue: Wyss Center in Geneva, Switzerland

If you are interested in meeting the Pharnext management team during this event, please send an email to Anne Hennecke at anne.hennecke@mc-services.eu.

About Pharnext
Pharnext is an advanced clinical-stage biopharmaceutical company founded by renowned scientists and entrepreneurs including Professor Daniel Cohen, a pioneer in modern genomics. Pharnext has two lead products in clinical development. PXT3003 is currently in an international Phase 3 trial for the treatment of Charcot-Marie-Tooth disease type 1A and benefits from orphan drug status in Europe and the United States. PXT864 has generated positive Phase 2 results in Alzheimer’s disease. Pharnext is the pioneer of a new drug discovery paradigm: PLEOTHERAPY™. The Company identifies and develops synergic combinations of repositioned drugs at new optimal lower doses. These PLEODRUG™ offer several key advantages: efficacy, safety and intellectual property including several product or composition of matter patents already granted. The Company is supported by a world-class scientific team.

The company Pharnext is listed on Euronext Growth Stock Exchange in Paris (ISIN code: FR00111911287).
For more information, visit www.pharnext.com

Contacts

Pharnext
Xavier Paoli, +33 (0)1 41 09 22 30
Chief Commercial Officer
contact@pharnext.com
or
Invest or Relations (Europe)
MC Services AG
Anne Hennecke, +49 211 529252 22
anne.hennecke@mc-services.eu
or
Investor Relations (U.S.)
Stern Investor Relations, Inc.
Matthew Shinseki, +1 212 362 1200
matthew@sternir.com
or
Financia l Communication (France)
Actifin
Stéphane Ruiz, +33 (0)1 56 88 11 15
sruiz@actifin.fr
or
Media Relations (Europe)
ALIZE RP
Caroline Carmagnol
Margaux Pronost
+33 (0)1 44 54 36 64
pharnext@alizerp.com
or
Media Relations (U.S.)
RooneyPartners
Marion Janic
+1 212 223 4017
mjanic@rooneyco.com
Deze bekendmaking is officieel geldend in de originele brontaal. Vertalingen zijn slechts als leeshulp bedoeld en moeten worden vergeleken met de tekst in de brontaal, die als enige rechtsgeldig is. Check out our twitter: @NewsNovumpr